Oncorus has raised $79.5 million to advance oncolytic viruses. The series B round equips Oncorus to move its lead prospect into the clinic and nominate an intravenously administered viral candidate early next year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,